NeuroVision vs Standard Neuromonitoring
Primary Purpose
Neurologic Deficits
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NeuroVision® IONM
Hospital Based IONM
Sponsored by
About this trial
This is an interventional prevention trial for Neurologic Deficits
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing a primary single or multilevel lateral spinal surgery procedures for degenerative pathology Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, central stenosis, foraminal stenosis herniated nucleus pulposus, degenerative disc disease, spondylosis, and osteophytic complexes
- Patients able to provide informed consent
Exclusion Criteria:
- Active infection
- Active or history of malignancy
- Spinal traumatic injury within the past 2 years
Sites / Locations
- Rush University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
NeuroVision® IONM
Conventional hospital based IONM
Arm Description
Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
Outcomes
Primary Outcome Measures
Incidence of new-onset neurological injury
Decreased somatosensory evoked potentials (SSEP) and transcranial MEPs (tcMEPs)
Secondary Outcome Measures
Cost analysis of IONM use
Difference in costs of hospital IONM and Neurovision
False positive and false negative events in each modality
Incorrect labeling of SSEP, tcMEP, and surface electromyography (sEMG) signals
Adverse Events
Post-operative nausea and vomiting, Gastro-esophageal reflux, ileus, urinary tract infection, venous thromboembolic events, Respiratory depression/airway compromise,m renal insufficiency, wound complications
Full Information
NCT ID
NCT04639297
First Posted
December 17, 2019
Last Updated
March 13, 2023
Sponsor
Rush University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT04639297
Brief Title
NeuroVision vs Standard Neuromonitoring
Official Title
NeruoVision Versus Standard Hospital Neuromonitoring, Influence on the Rate of Neurologic Injury Following Spine Surgery? A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 28, 2020 (Actual)
Primary Completion Date
December 20, 2024 (Anticipated)
Study Completion Date
December 20, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rush University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
The purpose of this study is to perform a prospective, randomized, controlled clinical trial to assess the utility of IONM in patients undergoing primary, single or multilevel lateral spinal procedures. Subjects will be randomized to undergo a lateral spine surgery with the use of NeuroVision® IONM or conventional hospital based IONM to assess incidence of new-onset neurological injury.
Detailed Description
Elective spinal surgery for the correction of degenerative spinal pathology may involve significant intraoperative risks that can influence postoperative neurologic outcomes. Spinal cord monitoring had made it possible to track the spine and nerve root sensory and motor tracts. This has improved the ability to conduct minimally invasive surgery by allowing surgeons to operate without direct visualization of the neurologic elements.
Intraoperative neuromonitoring (IONM) of the spinal cord is primarily accomplished by both somatosensory evoked potentials (SSEP) and transcranial motor evoked potentials (tcMEPs). Due to a shortage in personnel trained to evaluate neuro-monitoring results, surgeon-driven systems have been established. An example of a surgeon driven monitoring system is NeuroVision®, which interacts with the surgeon during the operation by providing real-time visible and auditory tcMEP and compound muscle action potential (CMAP) waveforms. This stands in comparison to hospital based methods of IONM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurologic Deficits
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
148 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
NeuroVision® IONM
Arm Type
Experimental
Arm Description
Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
Arm Title
Conventional hospital based IONM
Arm Type
Active Comparator
Arm Description
Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
Intervention Type
Device
Intervention Name(s)
NeuroVision® IONM
Intervention Description
Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Intervention Type
Device
Intervention Name(s)
Hospital Based IONM
Intervention Description
Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Primary Outcome Measure Information:
Title
Incidence of new-onset neurological injury
Description
Decreased somatosensory evoked potentials (SSEP) and transcranial MEPs (tcMEPs)
Time Frame
Enrollment up to 2 years postoperatively
Secondary Outcome Measure Information:
Title
Cost analysis of IONM use
Description
Difference in costs of hospital IONM and Neurovision
Time Frame
Enrollment up to 1 month post-operative
Title
False positive and false negative events in each modality
Description
Incorrect labeling of SSEP, tcMEP, and surface electromyography (sEMG) signals
Time Frame
Intraoperatively up to 1 day post-operative
Title
Adverse Events
Description
Post-operative nausea and vomiting, Gastro-esophageal reflux, ileus, urinary tract infection, venous thromboembolic events, Respiratory depression/airway compromise,m renal insufficiency, wound complications
Time Frame
Postoperative to documented progress assessed up to 2 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients undergoing a primary single or multilevel lateral spinal surgery procedures for degenerative pathology Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, central stenosis, foraminal stenosis herniated nucleus pulposus, degenerative disc disease, spondylosis, and osteophytic complexes
Patients able to provide informed consent
Exclusion Criteria:
Active infection
Active or history of malignancy
Spinal traumatic injury within the past 2 years
Facility Information:
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kern Singh, MD
Phone
312-432-2888
Email
singh.research@rushortho.com
12. IPD Sharing Statement
Learn more about this trial
NeuroVision vs Standard Neuromonitoring
We'll reach out to this number within 24 hrs